Skip to content
Screener

ImmunityBio, Inc. IBRX Return on equity

Discontinued — last reported Q3 '20

Return on equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
46.7%+17.8pp
Johnson & Johnson logo
Johnson & JohnsonJNJ
25.7%-4.5pp
Merck & Co. logo
Merck & Co.MRK
19%-20.3pp
Gilead Sciences logo
Gilead SciencesGILD
-20.6%-53.8pp
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-53.6%-22.6pp
Aura Biosciences, Inc. logo
Aura Biosciences, Inc.AURA
-95.6%+222pp

Other financials

Income statement

See full
Revenue$44.2M+168%
Gross profit$44.0M+167%
Operating income-$69.8M-8.3%
Net income-$632.8M-388%
EPS (diluted)-$0.62-313%

Balance sheet

See full
Cash & equivalents$205.2M+238%
Total debt$445.4M+32.2%
Total equity-$870.0M-47.1%
Total assets$646.6M+113%

Cash flow

See full
Operating cash flow-$75.4M+12.3%
CapEx$1.8M+58.4%
Free cash flow-$77.1M+11.4%

Valuation

See full
Market cap$7.68B+242%
Enterprise value$7.92B+227%
P/S54.5×+14.8×

Profitability

See full
Gross margin99.3%-0.5pp
Operating margin-185.4%-83.3pp
Net margin-606.2%-212pp
FCF margin-212%-95.8pp

Returns & leverage

See full
Debt / equity0.1×—
Current ratio6.7×+4.4×

Where this comes from

Calculated from ImmunityBio, Inc.’s reported figures.

net income/total stockholders equity=-119.3%

Based on trailing twelve months.

The source filing: ImmunityBio, Inc.’s 10-Q, filed November 12, 2021. Open the filing →

Filed
Nov 12, 2021, 4:38 PM EST
Fiscal quarter
Q3 FY2021
Calendar quarter
Q3 2021
Accession
0001326110-21-000009

FAQ

What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.